[go: up one dir, main page]

WO2015014291A1 - Procédé d'amplification et d'activation de cellules lymphatiques par culture en milieu asérique - Google Patents

Procédé d'amplification et d'activation de cellules lymphatiques par culture en milieu asérique Download PDF

Info

Publication number
WO2015014291A1
WO2015014291A1 PCT/CN2014/083368 CN2014083368W WO2015014291A1 WO 2015014291 A1 WO2015014291 A1 WO 2015014291A1 CN 2014083368 W CN2014083368 W CN 2014083368W WO 2015014291 A1 WO2015014291 A1 WO 2015014291A1
Authority
WO
WIPO (PCT)
Prior art keywords
serum
culture
lymphocytes
cell
free medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2014/083368
Other languages
English (en)
Chinese (zh)
Inventor
邵谊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IMMUNOTECH BEIJING Ltd
Original Assignee
IMMUNOTECH BEIJING Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IMMUNOTECH BEIJING Ltd filed Critical IMMUNOTECH BEIJING Ltd
Publication of WO2015014291A1 publication Critical patent/WO2015014291A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Definitions

  • the present invention relates to the field of immunotherapy, and in particular to a method for activating lymphocytes activated by serum-free culture. Background technique
  • Adoptive cellular immunotherapy is a method of tumor treatment after in vitro stimulation of lymphocytes by stimulator culture. Since the 1980s, the therapeutic effect of cytokine IL-2 on tumors has been discovered. The clinical application of cellular immunotherapy has rapidly expanded. Lymphokine-activated killer cells (LAK) and tumor-infiltrating lymphocytes have been cultured. TIL), cytokine-activated killer cells (CIK).
  • LAK Lymphokine-activated killer cells
  • TIL tumor-infiltrating lymphocytes
  • CIK cytokine-activated killer cells
  • Yamazaki T et al. reported in the Lancet a randomized controlled clinical trial of in vitro expansion of autologous lymphocytes to prevent tumor recurrence after liver cancer surgery. The results showed that this non-specific immunotherapy greatly prolonged the survival time of patients with liver cancer, and there was a certain correlation between the amount of transfused cells and the killing performance and efficacy. It is a promising method for tumor treatment.
  • the present invention provides a method for activating activated lymphocytes by serum-free culture, the method comprising:
  • lymphocyte activation step in which a biological sample containing lymphocytes is contacted with a lymphocyte activating agent coated on a culture container and cultured in a serum-free medium for 3-6 days;
  • step (b) a first amplification step, wherein the culture obtained in the step (a) is added to a serum-free medium having a volume of 0.8 to 1.2 times, and further cultured for 1-3 days;
  • step c) a third amplification step, wherein the culture obtained in the step c) is added with a serum-free medium having a volume of 2-4 times, and cultured for 4-6 days;
  • step d) a fourth amplification step, wherein a culture medium obtained in the step d) is added with a serum-free medium having a volume of 0.5 to 1.5 times, and cultured for 4-6 days;
  • step (f) Harvesting the amplified activated lymphocytes obtained in step (e).
  • the lymphocyte activator used in the methods of the invention is an anti-CD3 antibody.
  • the same serum-free medium is used in the method of the invention.
  • the serum-free medium used in the methods of the invention contains cytokines.
  • the cytokines can include IL-2, IL-7, and INF-Y.
  • the concentration of IL-2 in the medium used in the method of the present invention may be 750-1500 U/ml, for example 1000 U/ml ; the concentration of IL-7 may be 1-30 U/ml, for example 20 U/ml; INF-
  • the concentration of ⁇ can be 750-1500 U/ml, for example 1000 U/ml.
  • the serum-free medium used in the method of the invention is X-VIV015, TexMACS or IMSF100 medium. More preferably, the serum-free medium used is IMSF100 medium.
  • lymphocytes in the biological sample can be amplified 100 to 1000 times.
  • the expanded cells are predominantly CD8+ T cells, for example, CD8+ T cells can be >50% of the activated activated lymphocytes.
  • the activity of the expanded activated lymphocytes is maintained for 12 hours.
  • Figure 1 shows a flow chart of a method for amplifying activated lymphocytes.
  • Figure 2 is a graph showing the time course of activated activated lymphocyte viability.
  • Figure 3 shows a comparison of the amplification performance and statistical analysis of the five media.
  • Figure 4 shows the percentage of cell phenotype and statistical analysis after amplification of different media.
  • the present invention provides a method for efficiently amplifying activated lymphocytes, which is cultured using a serum-free medium, which is safe, efficient, and has good product stability and is suitable for mass production. Optimized culture/amplification
  • the present invention provides a method of amplifying activated lymphocytes, the method comprising the following steps:
  • lymphocyte activation step in which a biological sample containing lymphocytes is contacted with a lymphocyte activating agent coated on a culture container and cultured in a serum-free medium for 3-6 days;
  • step (b) a first amplification step, wherein the culture obtained in the step (a) is added to a serum-free medium having a volume of 0.8-1.2 times, and further cultured for 1-3 days;
  • step (c) a second amplification step, wherein the culture obtained in the step (b) is added to a serum-free medium having a volume of 1-1.5 times, and cultured for one to three days;
  • step c) a third amplification step, wherein the culture obtained in the step c) is added with a serum-free medium having a volume of 2-4 times, and cultured for 4-6 days;
  • step d) a fourth amplification step, wherein a culture medium obtained in the step d) is added with a serum-free medium having a volume of 0.5 to 1.5 times, and cultured for 4-6 days;
  • step (f) Harvesting the amplified activated lymphocytes obtained in step (e).
  • the number and volume of medium additions and the culture time of each step are optimized.
  • the method of the invention allows amplification of samples of different patient origins using substantially uniform conditions and procedures. For large numbers of samples, amplification can be performed simultaneously to achieve scale production.
  • the starting cell raw material used for amplification is generally derived from the peripheral blood of the patient, and patients of different genders, ages, and disease states cause a large difference in cells before culture.
  • cells of relatively uniform quantity and quality can be obtained, conforming to uniform quality standards, and being advantageous for commercial applications.
  • lymphocytes of 143 patients were amplified using the method of the present invention, and all of them were efficiently amplified, and the amplification factor was about 100 to about 1000 times, and the number of cells and cell phenotype after culture were compared.
  • the coefficient of variation before culture was significantly reduced by 62 to 85% (Table 5), which means that the cell preparation with higher quality can be obtained by the method of the present invention.
  • Lymphocytes that can be cultured and expanded using the methods of the invention can be derived from peripheral blood lymphocytes.
  • the lymphocytes to be expanded may also be lymphocytes present in other biological samples, such as epithelial lymphocytes, intratumoral infiltrating lymphocytes, cancerous ascites, or infiltrating lymphocytes in pleural fluid. Due to the simple separation of lymphocytes in peripheral blood, the high survival rate of lymphocytes after isolation, etc. Therefore, it is preferred to use lymphocytes isolated from fresh peripheral blood.
  • the "biological sample containing lymphocytes" in the method of the present invention refers to isolated peripheral blood mononuclear cells
  • PBMC peripheral blood mononuclear cells
  • the amount of initial peripheral blood mononuclear cells used in the method of the present invention can be as low as 1 X 10 7 ⁇ 4 X 10 7 cells, which is equivalent to only about 20 ml of peripheral blood in normal humans, and 1 X 10 can be obtained after amplification.
  • 9 ⁇ 12 X 10 9 lymphocytes mainly composed of killer T cells. A lower initial cell volume avoids a large amount of blood sampling to the patient.
  • activated lymphocytes refers to lymphocytes stimulated by specific antigens or non-specific lymphocyte stimulants/molecules which are capable of synthesizing macromolecular substances (RNA, protein, DNA) and cytokines. After activation, lymphocytes undergo cell proliferation and differentiate into progeny effector cells and memory cells of different functions.
  • lymphocyte activator refers to a reagent/molecule capable of stimulating lymphocyte activation.
  • an anti-CD3 antibody can be used as a lymphocyte activating agent which stimulates CD3 molecules on the surface of T cells and efficiently activates T lymphocytes through T cell receptors.
  • Lymphocyte mitogens are another class of potent lymphocyte activators. These molecules rapidly activate lymphocytes and do not pass through T lymphocyte receptors.
  • lymphocyte activator is an anti-CD3 antibody.
  • the lymphocyte activating agent is an anti-CD3 antibody coated (: immobilized:) on the surface of the culture vessel.
  • immobilized anti-CD3 antibody is preferred because it mainly activates CD8+ T cells having a cell killing function, which is particularly advantageous for increasing the antitumor activity of the expanded lymphocytes.
  • a method of immobilizing an anti-CD3 antibody is known, and for example, immobilization can be carried out as follows.
  • the anti-CD3 antibody When the anti-CD3 antibody is immobilized in a culture container, the anti-CD3 antibody can be diluted with a sterile sodium phosphate buffer (PBS) to a concentration of 1 to 50 ⁇ g/ml. When the concentration is less than 1 ⁇ g/ml, the proliferation of T cells tends to be insufficient. When the proliferation of T cells exceeds 50 ⁇ g/ml, the proliferation of T cells is sufficient, but the free anti-CD3 antibody which is not immobilized on the insoluble carrier tends to increase. .
  • the dilution liquid is not particularly limited as long as it is a physiological solution such as a sterilized sodium phosphate buffer solution, and albumin, agarose or the like may be added as a protective agent.
  • the diluted anti-CD3 antibody was aseptically plated on the bottom surface of the culture flask.
  • the reaction temperature at the time of fixation is 4 to 40 ° C, more preferably 4 to 25 ° C, and most preferably 4 to 10 ° C.
  • Anti-CD3 antibody at less than 4 ° C The immobilization efficiency tends to decrease, and when it exceeds 40 ° C, the activity of the anti-CD3 antibody tends to decrease.
  • the reaction time at the time of immobilization is from 30 minutes to 24 hours, preferably from 1 hour to 24 hours. At less than 30 minutes, the immobilization amount of the anti-CD3 antibody tends to decrease, and when it exceeds 24 hours, the fixation time is too long, and the production efficiency tends to decrease.
  • the anti-CD3 antibody is immobilized in a culture container.
  • the culture can be transferred to a culture vessel containing no lymphocyte activating agent after the incubation step (a:), (b), W or d) for subsequent incubation.
  • cytokine used in the amplification of lymphocytes is optimized in the method of the present invention.
  • the cytokine uses a combination of IL-2, IL-7 and INF-Y.
  • IL-2 can amplify CD8+ T cells with high efficiency and specificity
  • CD8+ T cells are the most important cellular components of the immune system to exert anti-tumor effects.
  • IL-7 and INF- y additionally promote lymphocyte proliferation, for example, to maintain the viability of memory cells and reduce cell death after cell activation, thereby achieving the best cell expansion and cell activity.
  • the concentration of IL-2 may be 250-3000 U/ml, 500-2000 U/ml, 750-1500 U/ml, for example 1000 U/ml; the concentration of IL-7 may be 1-100 U/ml, 5-50 U/ml, 10-30 U/ml, eg 20 U/ml; INF- ⁇ concentration can be 250-3000 U/ml, 500-2000 U/ml, 750-1500 U /ml, for example 1000U/ml.
  • the cells expanded using the method of the present invention are mainly CD8+ T cells.
  • the proportion of CD8+ T cells in the activated activated lymphocytes can be >50%. Optimized serum-free medium
  • Cell culture media commonly used in the art such as RPMI-1640 or DMEM, must be supplemented with fetal bovine serum or human serum when culturing cells.
  • adding serum will cause some problems, such as the introduction of serum. Source pathogen contamination, possible differences between different batches of serum, risk of immune rejection, etc.
  • Some serum-free cell culture systems have been developed in the art. However, these serum-free culture systems cannot achieve high-efficiency amplification during lymphocyte culture, fail to meet clinical requirements for the number and activity of cells for treatment, and the obtained cells lose activity in a short period of time.
  • the present invention is directed to an existing serum-free cell culture method, which screens a serum-free medium suitable for amplifying lymphocytes, and avoids the above problems in combination with the optimized cytokine combination described above and an optimized culture step.
  • Serum-free media suitable for use in the methods of the invention include X-VIV015 (Lonza), TexMACS (Miltenyi Biotech) or IMSF100 (LYMMU OTECH) media.
  • the most preferred serum-free medium is IMSF100 medium.
  • An advantage of the method of the present invention is that the same medium (including the same optimized combination of cytokines) can be used during lymphocyte culture without changing in culture, which simplifies the culture step and facilitates large-scale operation, which is beneficial to Commercial application.
  • the method of the present invention has a stable cell culture efficiency as compared with other serum-free culture methods in the art, and can achieve or exceed the amplification efficiency of a culture system to which animal serum is added, and the obtained cell activity is stable and has a long expiration date.
  • lymphocytes in the biological sample can be amplified at least 10-fold, preferably at least 100-fold, more preferably at least 1000-fold.
  • the viability of the activated lymphocytes expanded using the method of the invention can be maintained for at least 4 hours, preferably at least 8 hours, more preferably at least 12 hours.
  • the invention also provides an immunotherapeutic method comprising administering to an individual an activated lymphocyte obtained by the method of the invention.
  • the lymphocytes obtained by the above amplification method are autologous lymphocytes, and the immunotherapy method comprises the following steps:
  • the lymphocytes used are derived from a small amount of peripheral blood of the patient himself. These lymphocytes can be activated and amplified up to 100-1000 times in a short period of time and then returned to the patient.
  • the activated cells obtained by the method of the present invention are mostly CD8+ T lymphocytes (: >50%:).
  • CD8+ T lymphocytes play an important role in killing virus-infected cells and cancer cells.
  • Human T lymphocytes include many specific cells directed against different antigens. These cells are cultured and have a wide range of recognition and killing effects against different tumor antigens/viral antigens.
  • the immunotherapeutic method of the present invention can be used to treat individuals suffering from, for example, tumors, infectious diseases, congenital or acquired immunodeficiency, and infectious diseases after infection and infection-induced tumors.
  • Tumors that can be treated using the immunotherapeutic methods of the invention include, but are not limited to, liver cancer, lung cancer, cardiac cancer, colon cancer, breast cancer, medulloblastoma, gastric cancer, renal cancer, and malignant melanoma, and individuals with tumors It can be an individual who is receiving radiation therapy and/or chemotherapy.
  • the invention also provides a pharmaceutical composition for immunotherapy comprising activated lymphocytes obtained by the method of the invention.
  • a pharmaceutical composition for immunotherapy comprising activated lymphocytes obtained by the method of the invention.
  • the method of amplifying activated lymphocytes provided by the present invention has the following advantages over the prior art:
  • the method of the present invention can be carried out using a serum-free medium which avoids pathogenic microbial contamination and other adverse factors affecting cell growth which may result from the use of serum, and also avoids possible safety factors.
  • the patient's own T lymphocytes can be efficiently activated and amplified in vitro by the method of the present invention, and 1 X 10 9 ⁇ 12 X 10 9 activation amplification can be obtained from 1 X 10 7 ⁇ 4 X 10 7 peripheral blood mononuclear cells.
  • Lymphocytes mainly composed of killer T cells, which are efficiently amplified from about 100 to about 1000 times, avoiding the need for traditional immune cell therapy to use a single mining machine to take a large amount of starting peripheral blood mononuclear cells to the patient's overall immune cells. The destructive effect of the system.
  • the cell activity is generally maintained at about 2 hours.
  • the method of the present invention produces cell activity and stability, and the cells can be stored for 12 hours without affecting the therapeutic effect.
  • the method of the invention has simple operation, uniformity of steps, low risk of error, and is particularly suitable for large-scale System production.
  • lymphocytes having relatively consistent quantity and quality can be obtained, which conform to uniform quality standards and are advantageous for commercial applications.
  • Example 1 Activated lymphocyte expansion in 143 patients
  • Peripheral blood was collected from a total of 143 patients, with different genders, ages, and tumor types.
  • the basic information of patients is shown in Tables 1, 2 and 3.
  • PBMC peripheral blood mononuclear cells
  • the supernatant was decanted, resuspended in 50 mL of saline, and centrifuged at 335 X g for 10 min.
  • the supernatant was decanted, and 5 mL of the injection was resuspended in physiological saline, and the cells were counted by mixing the ⁇ cell suspension.
  • the physiological saline for injection was supplemented to 50 mL, and centrifuged at 223 X g for 10 minutes.
  • the supernatant was decanted, resuspended in 50 mL of serum-free cell medium IMSFIOO, and inoculated into a T225 flask coated with anti-human CD3 antibody, and placed in a cell culture incubator for initiation.
  • the cell culture flask After inoculation for 3 days, the cell culture flask was taken out from the incubator, and the serum-free cell culture medium IMSFIOO (containing IL-2 1000 U/ml, IL-7 20 U/ml, INF- y lOOOU/ml) was poured into 50 mL. The cell culture flask is returned to the cell culture incubator for cultivation.
  • the first addition of the step can be carried out for a period of not more than three days, for example, at the latest on the sixth day after the inoculation.
  • This second addition step can be postponed no more than two days, for example at the latest on the third day after the first addition.
  • the cells were cultured for another day, and the cell culture flask was taken out from the incubator, and the wall was tapped to completely detach the cells from the bottom of the bottle, and the cells were counted.
  • samples with a cell density of not less than IX 10 6 / mL do the following: Cell suspension in culture flask and 750 mL serum-free cell culture medium IMSFIOO (with IL-2 1000 U/ml) through a 60 mL syringe sleeve , IL-7 20U/ml, INF- y lOOOU/ml) All were poured into a new cell culture bag, the tube was closed, and samples were taken for sterility inspection. The cell culture bag is returned to the incubator for cultivation.
  • the third addition step can be postponed no more than two days, for example at the latest on the third day after the second addition.
  • the liquid in the bag A is completely flowed into the bag B, and then mixed, and then returned to the bag A, 1000 mL.
  • the amount of liquid in both bags was 1000 mL.
  • the tube is sealed and samples are taken for sterility inspection.
  • Two bags of cells were returned to the incubator for culture.
  • the fourth addition step can be postponed no more than two days, for example at the latest on the sixth day after the third addition.
  • culture for another 4 days take a bag of cells from the incubator to the biosafety cabinet, divide the cell suspension into four 250 mL centrifuge tubes, and centrifuge at 931 X g for 5 minutes. Pour off the supernatant and shake off the sediment.
  • Another bag of cells from the same batch was removed from the incubator, and the cell suspension was equally divided into four identical 250 mL centrifuge tubes and centrifuged at 931 X g for 5 minutes. Pour off the supernatant and shake off the pellet.
  • Four tubes of cells were combined into two tubes, and the physiological saline for injection was separately replenished to 250 mL, and centrifuged at 931 Xg for 5 minutes.
  • the supernatant was decanted and the pellet was shaken off. Then, the cells in the two tubes were washed three times with 200 mL of physiological saline for injection, combined into one tube, and mixed and sampled for cell counting. After centrifugation at 931 X g for 5 minutes, the supernatant was decanted and the cells were resuspended in saline with injection containing 1% human albumin. The cell suspension is then transferred to a disposable plastic transfer bag to form a cell preparation.
  • the harvesting step can be postponed no more than two days, for example at the latest on the sixth day after the fourth addition.
  • lymphocytes of all 143 patients obtained high-efficiency amplification using the method of the present invention. Moreover, the number of cells and the cell phenotype after culture were significantly lower than those before culture, and the decrease was 62-85%, that is, the cell product with more consistent quality could be obtained by the method of the present invention.
  • Example 2 Stability analysis of amplified activated lymphocytes
  • the activated lymphocyte products amplified by the three batches according to the method of the present invention are divided into two parallel groups, one group is stored at 2-8 ° C, and one group is stored at room temperature (15-25 ° C), every 4
  • the cell activity was measured at half hour (Trypan blue staining and viable cell count under the microscope:), and the cell activity time curve was plotted. The results are shown in Table 6 below and Figure 2.
  • the activated lymphocytes expanded according to the method of the present invention are stored under two temperature conditions, and there is no significant difference in cell activity changes (p>0.05), and can be maintained at more than 85% within 12 hours, which is consistent with the return of the human body. Requirements.
  • Group A samples were stored at 2-8 ° C, and Group B samples were stored at room temperature. "Al, 2, 3" represent three batches of cell products, respectively. Common cell cultures reported by (GIBCO), TexMACS (Miltenyi Biotech) and IMSF100 (LYMMU OTECH), and literature (Hoyle, C., et al., Blood, 1998. 92(9): p. 3318-27.) Base RPMI-1640 (GIBCO) performance parameters in the culture method of the present invention.
  • Peripheral blood from 3 normal individuals was collected and mononuclear cells were isolated.
  • the cells were divided into five groups (RPMI-1640 containing 10% fetal bovine serum, X-VIV015, TexMACS, AIM-V and IMSF100), and the same number of cells were inoculated, and culture was carried out using the culture step of the present invention.
  • Peripheral blood 120 ml/person was collected, and PBMC of peripheral blood mononuclear cells was obtained by density gradient centrifugation (Ficoll method) under sterile conditions:).
  • PBMC peripheral blood mononuclear cells
  • Each person's cells were divided into 5 equal parts, using 50 ml of five mediums (both cytokine IL-2 1000 U/ml, IL-7 20 U/ml, INF- y 1000 U/ml, see table below) 7)
  • inoculate the LC-AC T225 cell culture flask coated with CD3+ antibody After resuspending, inoculate the LC-AC T225 cell culture flask coated with CD3+ antibody, and the number of cells inoculated is 1.2 X 10 7 /bottle, and the number of cells inoculated in each group is the same.
  • each cell culture flask was supplemented with 50 ml of the corresponding component medium.
  • each cell culture flask was supplemented with 140 ml of the corresponding component medium.
  • the cells were counted using a cell counting plate to determine the amplification ratio. Amplified cell viability was obtained by trypan blue staining and cell counting. Phenotypic assays of the expanded cells were determined by flow cytometry using FITC-labeled CD3 antibody, PerCP-Cy5.5-labeled CD4 antibody, and APC-labeled CD8 antibody.
  • Table 9 shows the results of cell viability assay. After 14 days of culture, there was no significant difference in cell viability. Table 9: Cell viability test results
  • AIM-V cannot be used to amplify activated lymphocyte culture, and IMSF100 has the best effect on amplifying activated lymphocyte culture.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention concerne un procédé d'amplification et d'activation de cellules lymphatiques par culture en milieu asérique. Le procédé comprend : a) l'étape d'activation des cellules lymphatiques, qui consiste à mettre un échantillon biologique contenant des cellules lymphatiques en contact avec un agent d'activation de cellules lymphatiques revêtu sur un récipient de culture et à les cultiver pendant 3 à 6 jours en milieu asérique ; b) une première étape d'amplification, qui consiste à ajouter la culture obtenue à l'étape (a) à un milieu asérique ayant un volume de 0,8 à 1,2 fois celui de la culture et à poursuivre la culture pendant 1 à 3 jours ; c) une deuxième étape d'amplification, qui consiste à ajouter la culture obtenue à l'étape (b) à un milieu asérique ayant un volume de 1 à 1,5 fois celui de la culture et à poursuivre la culture pendant 1 à 3 jours ; d) une troisième étape d'amplification, qui consiste à ajouter la culture obtenue à l'étape (c) à un milieu asérique ayant un volume de 2 à 4 fois celui de la culture et à poursuivre la culture pendant 4 à 6 jours ; e) une quatrième étape d'amplification, qui consiste à ajouter la culture obtenue à l'étape (d) à un milieu asérique ayant un volume de 0,5 à 1,5 fois celui de la culture et à poursuivre la culture pendant 4 à 6 jours pour obtenir ainsi les cellules lymphatiques activées et amplifiées selon l'invention.
PCT/CN2014/083368 2013-08-02 2014-07-31 Procédé d'amplification et d'activation de cellules lymphatiques par culture en milieu asérique Ceased WO2015014291A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310334666.6A CN103436492B (zh) 2013-08-02 2013-08-02 通过无血清培养扩增活化淋巴细胞的方法
CN201310334666.6 2013-08-02

Publications (1)

Publication Number Publication Date
WO2015014291A1 true WO2015014291A1 (fr) 2015-02-05

Family

ID=49690210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/083368 Ceased WO2015014291A1 (fr) 2013-08-02 2014-07-31 Procédé d'amplification et d'activation de cellules lymphatiques par culture en milieu asérique

Country Status (2)

Country Link
CN (1) CN103436492B (fr)
WO (1) WO2015014291A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112251407A (zh) * 2020-11-03 2021-01-22 广州康琪莱精准医疗科技有限公司 一种脐带血cik细胞的扩增培养方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421716D0 (en) * 2014-12-05 2015-01-21 King S College London Cell expansion procedure
CN112662625B (zh) * 2021-01-18 2023-03-17 曹彤 一种t细胞培养基及其用于t细胞的扩增培养方法
CN116355845B (zh) * 2021-12-28 2024-03-26 北京永泰生物制品有限公司 一种质量稳定可控的扩增活化淋巴细胞的方法及其用于抗肿瘤用途
CN116355846B (zh) * 2021-12-28 2025-10-28 北京永泰生物制品有限公司 一种质量稳定可控的扩增活化淋巴细胞的方法及其用于防治神经科疾病中的用途
CN114984048A (zh) * 2022-06-16 2022-09-02 浙江百越生物技术有限公司 一种预防与治疗老年人行动迟缓的细胞疗法
CN120283043A (zh) * 2022-12-02 2025-07-08 上海药明巨诺生物医药研发有限公司 一种细胞培养组合物
CN117965445B (zh) * 2024-04-02 2024-06-25 上海药明巨诺生物医药研发有限公司 一种用于细胞培养的组合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120550A2 (fr) * 2004-06-04 2005-12-22 Cel-Sci Corporation Procede permettant de modifier le rapport cd4/cd8 et l'infiltrat cellulaire mononucleaire d'une tumeur
WO2007071389A1 (fr) * 2005-12-21 2007-06-28 Sentoclone Ab Méthode de traitement de cancer disséminé
CN101386840A (zh) * 2008-10-31 2009-03-18 江苏省人民医院 Cd3-cd56+nk细胞高效扩增培养系统的构建方法
CN101418283A (zh) * 2007-10-23 2009-04-29 范云峰 一种简单高效地制备cik细胞的方法
CN102174469A (zh) * 2011-01-26 2011-09-07 宋鑫 一种有效培养肿瘤浸润淋巴细胞的方法
CN102827808A (zh) * 2012-09-27 2012-12-19 高岱清 一种制备cik细胞的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1990044A (zh) * 2005-12-30 2007-07-04 上海中科英达生物技术有限公司 人体免疫活性细胞dccik抗肿瘤细胞制剂的制备方法及应用
CN101063108A (zh) * 2007-04-25 2007-10-31 哈尔滨医科大学 一种高增殖力、高细胞毒活性cik细胞的制备方法
WO2011103882A1 (fr) * 2010-02-24 2011-09-01 Ingo Schmidt-Wolf Procédé de production d'une population de cellules cik et de cellules nk
CN102352342B (zh) * 2011-09-30 2013-05-22 上海柯莱逊生物技术有限公司 一种用于扩增cik的方法及一种cik细胞制剂
CN102517213B (zh) * 2011-12-29 2013-09-11 辽宁迈迪生物科技有限公司 用于t淋巴细胞的体外培养试剂盒
CN103013914B (zh) * 2012-12-13 2014-12-03 吉林省拓华生物科技有限公司 体外培养杀伤性t细胞的方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120550A2 (fr) * 2004-06-04 2005-12-22 Cel-Sci Corporation Procede permettant de modifier le rapport cd4/cd8 et l'infiltrat cellulaire mononucleaire d'une tumeur
WO2007071389A1 (fr) * 2005-12-21 2007-06-28 Sentoclone Ab Méthode de traitement de cancer disséminé
CN101418283A (zh) * 2007-10-23 2009-04-29 范云峰 一种简单高效地制备cik细胞的方法
CN101386840A (zh) * 2008-10-31 2009-03-18 江苏省人民医院 Cd3-cd56+nk细胞高效扩增培养系统的构建方法
CN102174469A (zh) * 2011-01-26 2011-09-07 宋鑫 一种有效培养肿瘤浸润淋巴细胞的方法
CN102827808A (zh) * 2012-09-27 2012-12-19 高岱清 一种制备cik细胞的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AYELLO, J. ET AL.: "Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: Implications for adoptive cellular immunotherapy", EXPERIMENTAL HEMATOLOGY, vol. 37, no. 10, 31 October 2009 (2009-10-31), pages 1216 - 1229, XP026612092, DOI: doi:10.1016/j.exphem.2009.07.009 *
LUO, HAIHUA ET AL.: "Methods for expansion of human CD 8+ memory T cells in vitro", CHINESE JOURNAL OF PATHOPHYSIOLOGY, vol. 29, no. 7, 31 July 2013 (2013-07-31), pages 1339 - 1344 *
WANG, XIAOHUA.: "Effects of various factors on proliferation capacity and cytotoxicy of induced CIK of patients with tumor in vitro", CHINA JOURNAL OF MODERN MEDICINE, vol. 17, no. 23, 31 December 2007 (2007-12-31), pages 2864 - 2867 *
WENDELBO ET AL.: "Functional Evaluation of Proliferative T Cell Responses in Patients with Severe T Lymphopenia: Characterization of Optimal Culture Conditions and Standardized Activation Signals for a Simple Whole Blood Assay", JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, vol. 12, 31 December 2003 (2003-12-31), pages 525 - 535 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112251407A (zh) * 2020-11-03 2021-01-22 广州康琪莱精准医疗科技有限公司 一种脐带血cik细胞的扩增培养方法

Also Published As

Publication number Publication date
CN103436492A (zh) 2013-12-11
HK1192282A1 (zh) 2014-08-15
CN103436492B (zh) 2016-03-02

Similar Documents

Publication Publication Date Title
CN102112600B (zh) 自然杀伤细胞的增殖方法
WO2015014291A1 (fr) Procédé d'amplification et d'activation de cellules lymphatiques par culture en milieu asérique
CN105101978B (zh) Nk细胞强化型血液制剂的制造方法
CN108699523B (zh) Nk细胞培养用培养基添加试剂盒及利用所述试剂盒的nk细胞培养方法
CN101302491A (zh) 高效扩增活化淋巴细胞的方法和培养系统
US20140073050A1 (en) Method for activation treatment of antigen-presenting cell
WO2020247802A9 (fr) Méthodes de fabrication de lymphocytes t par tri direct et compositions associées
KR20240005984A (ko) 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
CN104321425A (zh) 用于诱导和扩增源自外周血单个核细胞的自然杀伤细胞的方法
CN108220235A (zh) 一种体外活化扩增人自然杀伤（nk）细胞的方法及其专用培养体系
WO2011052638A1 (fr) Procédé de production de cellules tueuses induites par la cytokine
CN108379569B (zh) 高效荷载肿瘤抗原的dc疫苗及其诱导扩增肿瘤抗原特异性ctl的方法
EA016168B1 (ru) Способ получения т-клеточной популяции и ее применение
JP2017061558A (ja) Ｔｈ１特性と細胞溶解性を発現する細胞
CN116179486B (zh) 一种肿瘤浸润淋巴细胞的制备方法
JP4275680B2 (ja) リンパ球の活性・増殖に係る培養方法
CN110747167B (zh) 一种半合子bak细胞的制备方法及其应用
JP5825966B2 (ja) Ｃｄ５６陽性ｔ細胞増強方法
MX2009001269A (es) Metodo de proliferacion de celulas asesinas activadas por linfocina.
CN116179483B (zh) 一种体外快速扩增干细胞样记忆性宫颈癌肿瘤浸润淋巴细胞的方法
CN111690608A (zh) 一种双抗体联合胸腺肽体外培养nk细胞试剂及试剂盒和培养方法
HK1192282B (en) Method for expanding activated lymphocyte by serum-free culture
TWI669400B (zh) 用於體外擴增自然殺手細胞及自然殺手ｔ細胞之無血清細胞培養液
CN114196629A (zh) 一种高效培养nkt细胞的试剂及其应用和nkt细胞的培养方法
CN116650629A (zh) 一种小鼠树突状细胞外泌体介导的肝癌疫苗的制备

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14832990

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14832990

Country of ref document: EP

Kind code of ref document: A1